{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:03:37Z","timestamp":1780347817440,"version":"3.54.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pemphigus is a life-threatening, chronic, autoimmune bullous disease affecting both the skin and the mucous membranes. Based on the mainstream concept that blister formation occurs upon binding of autoantibodies to their antigen proteins (desmoglein1, DSG1 and desmoglein3, DSG3), current therapies mostly aim to suppress the immune system. To avoid the severe side effects associated with the chronic use of immunosuppressive treatments, we have developed PC111, a fully human monoclonal antibody targeting human Fas ligand (FasL). We have provided a number of <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> evidences showing that soluble FasL induces keratinocyte apoptosis followed by acantholysis. An anti-murine FasL prevents blister formation in the pemphigus neonatal mouse model. To confirm the mechanism of action (MoA) and the efficacy of PC111 in a human pemphigus context, we used the keratinocyte dissociation assay and two independent Human Skin Organ Cultures (HSOC) pemphigus models. PC111 reduced acantholysis <jats:italic>in vitro<\/jats:italic>, as shown by the dose-dependent reduction of fragments in the monolayer cultures. In the first HSOC model, normal human skin was subcutaneously injected with a scFv antibody fragment directed against DSG1 and DSG3, resulting in a severe acantholysis (70-100%) after 24 hours. PC111 inhibited blister formation to around 50% of control. In the second model, normal human skin was injected with a mixture of pemphigus patients\u2019 autoantibodies resulting in a less severe acantholysis (20-30%). PC111 significantly suppressed blister formation to more than 75% up to 72 hours. These results confirm PC111 MoA and demonstrates the efficacy of the anti-FasL antibody also in a pemphigus setting.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1193032","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T19:59:00Z","timestamp":1689191940000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Blocking soluble Fas Ligand ameliorates pemphigus: PC111 efficacy in ex-vivo human pemphigus models"],"prefix":"10.3389","volume":"14","author":[{"given":"Roberta","family":"Lotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Hundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph M.","family":"Hammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brydon","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pincelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.3.1825","article-title":"Pemphigus vulgaris IgG directly inhibit desmoglein 3-mediated transinteraction","volume":"181","author":"Heupel","year":"2008","journal-title":"J Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.30784","article-title":"What protein kinases are crucial for acantholysis and blister formation in pemphigus vulgaris? A systematic review","volume":"237","author":"Brescacin","year":"2022","journal-title":"J Cell Physiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1163066","article-title":"Dsg3 epitope-specific signalling in pemphigus","volume":"14","author":"Schmitt","year":"2023","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.00934.x","article-title":"Apoptolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis","volume":"18","author":"Grando","year":"2009","journal-title":"Exp Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1023\/B:APPT.0000018795.05766.1f","article-title":"Possible apoptotic mechanism in epidermal cell acantholysis induced by pemphigus vulgaris autoimmunoglobulins","volume":"9","author":"Wang","year":"2004","journal-title":"Apoptosis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1995.tb07096.x","article-title":"Expression of the functional soluble form of human Fas ligand in activated lymphocytes","volume":"14","author":"Tanaka","year":"1995","journal-title":"EMBO J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2010.10.006","article-title":"Insights into the molecular regulation of FasL (CD178) biology","volume":"90","author":"Lettau","year":"2011","journal-title":"Eu J Cell Biol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-6865(99)00038-2","article-title":"Apoptosis induced by death receptors","volume":"74","author":"Schneider","year":"2000","journal-title":"Pharm Acta Helv"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.23.4.1428-1440.2003","article-title":"Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex","volume":"23","author":"Holler","year":"2003","journal-title":"Mol Cell Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nature08402","article-title":"Membrane-bound Fas ligand only is essential for Fas-induced apoptosis","volume":"461","author":"O\u2019Reilly","year":"2009","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M212188200","article-title":"Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions","volume":"278","author":"Viard-Leveugle","year":"2003","journal-title":"J Biol Chem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)61239-4","article-title":"Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in pemphigus","volume":"167","author":"Arredondo","year":"2005","journal-title":"Am J Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12014.x","article-title":"Fas ligand in pemphigus sera induces keratinocyte apoptosis through the activation of caspase-8","volume":"120","author":"Puviani","year":"2003","journal-title":"J Invest Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00370","article-title":"Soluble Fas ligand is essential for blister formation in pemphigus","volume":"9","author":"Lotti","year":"2018","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24185","article-title":"Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display","volume":"115","author":"Payne","year":"2005","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.291","article-title":"Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years","volume":"135","author":"Hammers","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1002\/cpph.56","article-title":"Translational use of a standardized full human skin organ culture model in autoimmune blistering diseases","volume":"85","author":"Burmester","year":"2019","journal-title":"Curr Protoc Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15721","article-title":"Inhibition of p38MAPK signalling prevents epidermal blistering and alterations of desmosome structure induced by pemphigus autoantibodies in human epidermis","volume":"177","author":"Egu","year":"2017","journal-title":"Br J Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23714.x","article-title":"In vitro keratinocyte dissociation assay for evaluation of the pathogenicity of anti-desmoglein 3 IgG autoantibodies in pemphigus vulgaris","volume":"124","author":"Ishii","year":"2005","journal-title":"J Invest Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/00236772221145647","article-title":"The human skin organ culture model as an optimal complementary tool for murine pemphigus models","volume":"16","author":"Hartmann","year":"2023","journal-title":"Lab Anim"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12513454","article-title":"Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum","volume":"67","author":"Schiltz","year":"1976","journal-title":"J Invest Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1313.040","article-title":"The interaction of pemphigus autoimmunoglobulins with epidermal cells: activation of the Fas apoptotic pathway and the use of caspase activity for pathogenicity tests of pemphigus patients","volume":"1050","author":"Frusic-Zlotkin","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1046\/j.0022-202x.2001.01643.x","article-title":"Immunologic and histopathologic characterization of an active disease mouse model for pemphigus vulgaris","volume":"118","author":"Ohyama","year":"2002","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15233","article-title":"Identification of novel therapeutic targets for blocking acantholysis in pemphigus","volume":"177","author":"Burmester","year":"2020","journal-title":"Br J Pharmacol"}],"updated-by":[{"DOI":"10.3389\/fimmu.2024.1331003","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1193032\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T10:59:32Z","timestamp":1706007572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1193032\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":24,"alternative-id":["10.3389\/fimmu.2023.1193032"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1193032","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fimmu.2024.1331003","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]},"article-number":"1193032"}}